Abstract
Hemophilia is understood as a disturbance of the blood coagulation system and includes hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), and von Willebrand’s disease (VWD). Because of limited resources, the project will concentrate on X-linked hemophilia A. The clinical phenotype of hemophilia A is highly variable, ranging from mild forms to very severe diseases including the formation of antibodies to exogenous factor VIII; substitution by exogenous factor VIII concentrates is the main form of medical treatment. In Germany, about 5800 patients are affected; the average cost for the treatment is about 100,000 DM per patient per year, totaling more than 500 million DM per year. Worldwide, only 20% of patients can be treated because of the expense of the therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Antonarakis, S.E.: Molecular genetics of coagulation factor VIII gene and hemophilia A. Hemophilia 4 (1998, Suppl. 2), 1–11.
Becker, J., Schwaab, R., Möller-Taube, A., Schwaab, U., Schmidt, W., Brackmann, H.-H., Grimm, T., Olek, K., Oldenburg, J.: Characterization of the factor VIII defect in 147 patients with sporadic Hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies. Am. J. Hum. Genet. 58 (1996) 657–670.
Brackmann, H.-H., Gormsen, J.: Massive factor VIII infusion in hemophilic patients with factor VIII inhibitor. Lancet II (1977) 933.
Brackmann, H.-H., Oldenburg, J., Schwaab, R.: Immune tolerance for the treatment of factor VIII inhibitors — Twenty years “Bonn Protocol”. Vox Sang. 70 (1996, Suppl. 1) 30–35.
Fallaux, F.J., Hoeben, R.C.: Gene therapy for the hemophiliacs. Curr.Opin.Hematol. 3, 1996, 385–389.
Gilles, J.G., Desqueper, B., Lenk, H., Vermylen, J., Saint-Remy, J.M.: Neutralizing antiidiotypic antibodies to factor VIII inhibitors after in patients with hemophilia A. J. Clin. Invest. 97 (1996) 1382–1388.
HAMSTeRS: Review: The molecular pathology of Hemophilia A. http://europium.csc.ac.uk (last updated version: May 4, 1999).
Lakich, D., Kazazian, H.H., Antonarakis, S.E., Gitschier, J.: Inversions disrupting the factor VIII gene are a common cause of severe hemophilia A. Nat. Genet. 5 (1993) 236–241.
Levinson, B., Kenwrick, S., Lakich, D., Hammonds, G., Gitschier, J.: A transcribed gene in an intron of the human factor VIII gene. Genomics 7 (1990) 1–11.
Oldenburg, J., Picard, J.K., Schwaab, R., Brackmann, H.-H., Tuddenham, E.G.D., Simpson, E.: HLA genotype of patients with severe Hemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb. Haemost. 77 (1997) 238–242.
Oldenburg, J., Schröder, J., Schmitt, C., Brackmann, H.-H., Schwaab, R.: Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype. Thromb. Haemost. 79 (1998) 452–453.
Sawamoto, Y., Prescott, R., Zhong, D., Saenko, E.L., Mauser-Bunschoten, E., Peerlinck, K., van den Berg, M., Scandella, D.: Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb. Haemost. 79 (1998) 62–68.
Scharrer, I., Neutzling, O.: Incidence of inhibitors in hemophiliacs (Review). Blood Coag. Fibrinol. 4 (1993) 753–758.
Schwaab, R., Brackmann, H.H., Meyer, C., Seehafer, J., Kirchgesser, M., Haack, A., Olek, K., Tuddenham, E.G.D., Oldenburg, J.: Hemophilia A: mutation type determines risk of inhibitor formation. Thromb. Haemost. 74 (1995) 1402–1406.
Tuddenham, E.G.D. et mult, al.: Database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene. Nucleic Acids Res. 19 (1991) 4821–4833.
Young, M., Inaba, H., Hoyer, L.W., Higuchi, M., Kazazian, H.H. jr., Antonarakis, S.E.: Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene. Am. J. Hum. Genet. 60 (1997) 565–573.
Zhong, D., Saenko, E.L., Shima, M., Felch, M., Scandella, D.: Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 92 (1998) 136–142.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Graw, J., Brackmann, HH., Oldenburg, J., Schramm, W., Schwaab, R. (2001). Genotype-Phenotype Correlation in Hemophilia A. In: Scharrer, I., Schramm, W. (eds) 30th Hemophilia Symposium Hamburg 1999. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18240-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-18240-2_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-67677-5
Online ISBN: 978-3-642-18240-2
eBook Packages: Springer Book Archive